Flamingo Therapeutics2023-02-14T20:19:39-08:00

We are Focused on
Clinical Execution.

Flamingo has a late-stage pipeline focused on delivering therapeutic benefit to patients living with cancer.  We believe our programs and approach address large unmet medical needs where RNA-targeting can be successful.

Our State-of-the-Art
Chemistries Drive Innovation.

At Flamingo, we understand drug development – and more importantly – we understand RNA therapeutic drug development. We know that robust and novel backbone chemistry is paramount when developing any RNA therapeutic, especially for difficult to treat cancers, where many modalities have failed to succeed.

Featured News

Flamingo Therapeutics Announces First Patient Dosed in Phase II PEMDA-HN Study for Head and Neck Squamous Cell Carcinoma (HNSCC)

Flamingo Therapeutics (“Flamingo”) today announced that the first patient has been dosed in its PEMDA-HN trial evaluating danvatirsen in combination with KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, in patients with recurrent/metastatic head and neck squamous cell

February 14, 2024|
Go to Top